Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 11Glioblastoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Lung Neoplasms 2Recurrence 1Neurotoxicity Syndromes 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Gliosarcoma 1Gastrointestinal Neoplasms 1Epilepsy 1Ependymoma 1Craniopharyngioma 1Cognitive Dysfunction 1Central Nervous System Neoplasms 1Central Nervous System Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Radiotherapy 2Mental Status and Dementia Tests 2motexafin gadolinium 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Procarbazine 1Modafinil 1Methotrexate 1Memantine 1Magnetic Resonance Spectroscopy 1Lithium Carbonate 1Lithium 1Donepezil 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Memantine × CNS × Clear all
NCT00566852 2017-08-21

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Radiation Therapy Oncology Group

Phase 3 Completed
554 enrolled 12 charts
CNS

Brain Neoplasms, Neoplasm Metastasis, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡